poisar

Stocks · News reference

BioLineRx And Hemispherian Announce New Preclinical Data Showing Strong Synergy Between GLIX1 And PARP Inhibitors In Patient-Derived Xenograft Model Of Ovarian Cancer

Jul 8, 2026, 11:07 AMBenzinga Newsdesk
Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BLRX
Source
benzinga
Observed
Jul 8, 2026, 11:07 AM
Checked
Jul 8, 2026, 11:15 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Jul 20, 2026, 11:07 AMBenzinga Newsdesk

    BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October

    Presentation Details:Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell LinesPresentation #: 1435ePPresentation type: e-PosterLocation: e-Poster

    Read original at benzinga
    BLRX
  2. Jun 16, 2026, 5:00 PMDelveinsight

    Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight

    Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.

    Read original at globenewswire-inc
    KZIAINOTLXBLRX
  3. May 29, 2026, 6:16 PMMotley Fool Transcribing

    BioLineRx (BLRX) Q1 2026 Earnings Transcript

    BioLineRx reported Q1 2026 results with a net loss of $2.6 million versus net income of $5.1 million in Q1 2025. The company initiated a Phase I/IIa trial for GLIX1 in glioblastoma with first patient dosed at NYU Langone Health, supported by preclinical data showing dose-dependent tumor growth inhibition. APHEXDA royalty revenues increased to $0.5 million from $0.3 million as Ayrmid's sales grew to $2.5 million. The company ended the quarter with $17.4 million in cash, sufficient to fund operations into H1 2027.

    Read original at the-motley-fool
    BLRX